Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00901264 · ClinicalTrials.gov registry record
Microculture Kinetic (MiCK) Apoptosis Test Results With Drug Treatment Results in Cancer Patients
A clinical trial of Cancer, sponsored by Pierian Biosciences.
- Completed
- Registry status
- 300
- Enrollment target
- 11
- Study locations
NCT00901264 is a study of Cancer that has completed, run by Pierian Biosciences. The registered enrollment target is 300 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (91% lower). The trial reports 11 study locations across 4 states.
The verdict
NCT00901264, a study of Cancer, has completed, sponsored by Pierian Biosciences.
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to correlate the results of the MICK assay with short- and long-term results of treatments in cancer patients and evaluate the role of the MiCK assay in guiding chemotherapy of cancer patients.
Conditions Studied
Study Locations (11)
Tennessee
- DiaTech Oncology - Brentwood
- Cumberland Medical Center - Crossville
- Middle Tennessee Medical Center - Murfreesboro
- Baptist Hospital - Nashville
- Nashville Oncology Associates - Nashville
- St. Thomas Research Institute, LLC - Nashville
- Tennessee Breast Specialists - Nashville
- Tennessee Toracic Surgical Specialists - Nashville
California
- Wilshire Oncology Medical Group, Inc - La Verne
Florida
- Tampa General Hospital - Tampa
Quebec
- DiaTech Oncology - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2008-12 |
| Est. Completion | 2012-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00901264
The ClinicalTrials.gov registry entry for NCT00901264 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Pierian Biosciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00901264 reports 11 study locations spanning 4 distinct geographic areas - top geographies include Tennessee, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00901264 about?
NCT00901264 is a clinical study titled "Microculture Kinetic (MiCK) Apoptosis Test Results With Drug Treatment Results in Cancer Patients". The purpose of this study is to correlate the results of the MICK assay with short- and long-term results of treatments in cancer patients and evaluate the role of the MiCK assay in guiding chemotherapy of cancer patients.
What is the current status of trial NCT00901264?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2008-12. Estimated completion is 2012-11.
What conditions does trial NCT00901264 study?
This clinical trial studies the following conditions: Cancer.
Who is sponsoring clinical trial NCT00901264?
This trial is sponsored by Pierian Biosciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00901264 being conducted?
This trial has 11 study locations across California, Florida, Tennessee, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.